Search

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

The findings demonstrate the benefit of clinic-level educational interventions

FAQ

Boehringer included on LinkedIn’s “Top Companies 2024” list

Investing in our people is at the core of what we do

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US

Find out more about the new name in the mastitis tube market, cutting down today's regular 5-day treatment to just 3: PolyMast from Boehringer Ingelheim.

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic

Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live

Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Big Little Things: In cancer, small things make a big impact

Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.

Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Achieving Health Equity: The Importance of Patient Input at Every Phase of Care

Learn more about how our BI Diversity and Inclusion Patient Council illuminates the impact of health inequities & how we can work together to be upstanders.

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Click here to read more on the annual National Veterinary Scholars Symposium, celebrating future veterinarians and scientists across the USA.

Family owned

Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E

Queen Latifah and Bernie Williams star

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Phase III EMPA-KIDNEY trial will stop early

The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

FAQ

Boehringer included on LinkedIn’s “Top Companies 2024” list

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Big Little Things: In cancer, small things make a big impact

Improving Access to Clinical Trials

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Achieving Health Equity: The Importance of Patient Input at Every Phase of Care

NVSS: The Future Vets & Scientists | Boehringer Ingelheim US

Family owned

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Phase III EMPA-KIDNEY trial will stop early

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care